Please use this identifier to cite or link to this item:
Title: Treatment of psoriasis with biologic agents in Malta
Authors: Mercieca, Liam
Boffa, Michael J.
Clark, Eileen
Scerri, Lawrence
Aquilina, Susan
Keywords: Psoriasis -- Treatment
Biological agents -- Therapeutic use
Issue Date: 2016
Publisher: Malta Medical Journal
Citation: Malta Medical Journal. 2016, Vol. 28(1), p. 27-32
Abstract: Introduction: Biologic therapy has revolutionalised the treatment of moderate to severe psoriasis leading to improved clinical outcomes and quality of life scores. This study aims to determine current biologic use in psoriatic patients at our Dermatology department at Sir Paul Boffa hospital, Malta. Method: All patients who were administered biologic therapy for psoriasis in Malta until the end of 2014 were included. Data included demographic details, disease duration and severity, biologic use and duration, previously attempted treatments, side effects, early and late response to biologic using Psoriasis Area Severity Index (PASI) scores and Dermatology Life Quality index (DLQI) scores. Results: A total of 36 patients were started on a biologic between 2009 and 2014 for psoriasis (M:25, F:11) with a mean age of 46.9 years. These included etanercept (n=22), infliximab (n=8), adalimumab (n=4) and ustekinumab (n=2). Secondary failure was the main reason why biologics were stopped and switched. Most patients had an improvement in their PASI scores after 2 to 4 weeks of starting the biologic and had a PASI 90 score improvement. All patients had more than a 5 point improvement in DLQI score. Discussion: Biologic use in our department is on the increase. Our patients had considerable improvements in their PASI and DLQI scores. Secondary failures have occurred usually after 2 to 4 years and switching has yielded positive results. Biologics are expensive drugs and recently we have switched to cheaper biosimilars. Doctors should be aware of the treatment options available for psoriasis patients, their possible side effects and when to refer to our department. In most cases a satisfactory response can be achieved.
Appears in Collections:MMJ, Volume 28, Issue 1
MMJ, Volume 28, Issue 1

Files in This Item:
File Description SizeFormat 
Treatment of psoriasis with biologic agents.pdf1.16 MBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.